CLINICAL TRIALS AND OBSERVATIONS Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study
نویسندگان
چکیده
1Princess Margaret Hospital, Toronto, ON; 2Amyloidosis Center, University of Heidelberg, Heidelberg, Germany; 3Boston University Medical Center, Boston, MA; 4Amyloidosis Research and Treatment Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Policlinico San Matteo, University of Pavia, Pavia, Italy; 5Hematology Department, Institute of Hematology and Oncology, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, University of Barcelona, Barcelona, Spain; 6Hôpital Saint Louis, Paris, France; 7Memorial Sloan-Kettering Cancer Center, New York, NY; 8Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA; 9Cedars-Sinai Medical Center, Los Angeles, CA; 10Johnson & Johnson Oncology Research & Development, Raritan, NJ; 11Millennium Pharmaceuticals Inc, Cambridge, MA; 12Johnson & Johnson Pharmaceutical Research & Development, Beerse, Belgium; 13Johnson & Johnson Oncology Research & Development, High Wycombe, United Kingdom; and 14Tufts Medical Center, Boston, MA
منابع مشابه
Regular Article CLINICAL TRIALS AND OBSERVATIONS Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis Donna E. Reece, Ute Hegenbart, Vaishali Sanchorawala, Giampaolo Merlini, Giovanni Palladini, Joan Bladé, Jean-Paul Fermand, Hani Hassoun, Leonard Heffner, Vishal Kukreti, Robert A. Vescio, Lixia Pei, Christopher Enny, Dixie-Lee Esseltine, Helgi van de Velde, Andrew Cakana, and Raymond L. Co...
متن کاملCLINICAL TRIALS AND OBSERVATIONS A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis
In this phase 1/2 study, we explored the feasibility and activity of an oral regimen of lenalidomide with low-dose dexamethasone and low-dose oral cyclophosphamide (RdC) in patients with primary systemic light chain amyloidosis. RdC was given for up to 12 cycles in prespecified cohorts at escalated doses: 13 patients were treated in phase 1 and 24 in phase 2; 65% were previously untreated, and ...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma
Bortezomib, a potent and reversible proteasome inhibitor, affects the myeloma cell and its microenvironment, resulting in downregulation of growth and survival signaling pathways and durable responses in patients with relapsed and refractory myeloma. Potential associations between baseline parameters and outcomes with bortezomib were explored in 202 patients who received bortezomib 1.3 mg/m2 tw...
متن کاملBrief Report CLINICAL TRIALS AND OBSERVATIONS A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis
In amyloid light chain (AL) amyloidosis, clonal plasma cells use proteasomes to cope with misfolded light chain-induced proteotoxicity, and theproteasome inhibitor bortezomib is a potential targeted therapy. Early reports supported this expectation, showing high response rates, particularly upfront. A prospective trial showed that single-agent bortezomib ishighlyand rapidlyeffective.Combination...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias
MS-275 is a benzamide derivative with potent histone deacetylase (HDAC) inhibitory and antitumor activity in preclinical models. We conducted a phase 1 trial of orally administered MS-275 in 38 adults with advanced acute leukemias. Cohorts of patients were treated with MS-275 initially once weekly 2, repeated every 4 weeks from 4 to 8 mg/m2, and after 13 patients were treated, once weekly 4, re...
متن کامل